Consequently, our data advocate the potential of MUL1 as a therapeutic target for drug development in the treatment of obesity, insulin resistance, NAFLD, and cardiometabolic diseases. The gene discussed is MUL1; the disease is metabolic dysfunction-associated steatotic liver disease.